Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
25
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,754.70 | 49.70 | 0.57% |
CAC 40 | 7,255.42 | 18.53 | 0.26% |
DAX 40 | 20,016.75 | 83.13 | 0.42% |
Dow JONES (US) | 44,729.29 | 52.71 | -0.12% |
FTSE 100 | 8,359.41 | 46.52 | 0.56% |
HKSE | 19,746.32 | 196.03 | 1.00% |
NASDAQ | 19,470.90 | 66.96 | 0.35% |
Nikkei 225 | 39,248.86 | 735.84 | 1.91% |
NZX 50 Index | 13,093.18 | 21.50 | -0.16% |
S&P 500 | 6,050.78 | 3.63 | 0.06% |
S&P/ASX 200 | 8,495.20 | 47.30 | 0.56% |
SSE Composite Index | 3,378.81 | 14.82 | 0.44% |